breast cancer glp 1 Frontiers The effect of GLP-1R agonists

The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course

We cover everything you need to know.

Understanding the biological, behavioral, and genetic factors behind this frustration can help you restart progress and achieve your goals

Purpose of Review Brain fog is a common, poorly understood condition with symptoms like forgetfulness, mental slowness, difficulty concentrating, word-finding issues, and mental cloudiness

Insurance coverage for GLP-1 weight loss drugs remains limited and unpredictable

Expert guidance on managing GI side effects.